Identification of druggable targets from the interactome of the Androgen Receptor and Serum Response Factor pathways in prostate cancer
Authors:
Open Access
- 13 December 2024
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (12) , e0309491
Abstract
Background: The Androgen Receptor (AR) pathway is crucial in driving the progression of prostate cancer (PCa) to an advanced state. Despite the introduction of second-generation AR antagonists, such as enzalutamide, majority of patients develop resistance. Several mechanisms of resistance have been identified, including the constitutive activation of the AR pathway, the emergence of AR spliced variants, and the influence of other signalling pathways. The Serum Response Factor (SRF) was previously identified as a possible player of resistance involved in a crosstalk with the AR signalling pathway. Elevated SRF levels in PCa patients were associated with disease progression and resistance to enzalutamide. However, the molecular mediators of the crosstalk between SRF and AR still need to be elucidated. The objective of this study was to identify common interactors of the AR/SRF crosstalk as therapeutic targets. Methods: Here we used affinity purification mass spectrometry (MS) following immunoprecipitation of SRF and AR, to identify proteins that interact with both SRF and AR. The list of common interactors was expanded using STRING. Four common interactors were functionally validated using MTT assays. Results: Seven common interactors were identified, including HSP70, HSP0AA1, HSP90AB1, HSAP5, PRDX1 and GAPDH. Pathway analysis revealed that the PI3k/AKT pathway was the most enriched in the AR/SRF network. Moreover, pharmacological inhibition of several proteins in this network, including HSP70, HSP90, PI3k and AKT, significantly decreased cellular viability of PCa cells. Conclusions: This study identified a list of AR/SRF common interactors that represent a pipeline of druggable targets for the treatment of PCa.Keywords
Funding Information
- Science Foundation Ireland (18/SIRG/5510)
- Irish Research Council (GOIPG/2023/4311)
This publication has 34 references indexed in Scilit:
- Allosteric inhibition of HSP70 in collaboration with STUB1 augments enzalutamide efficacy in antiandrogen resistant prostate tumor and patient-derived modelsPharmacological Research, 2023
- The Perseus computational platform for comprehensive analysis of (prote)omics dataNature Methods, 2016
- The FHL2 regulation in the transcriptional circuitry of human cancersGene, 2015
- Relationship between serum response factor and androgen receptor in prostate cancerThe Prostate, 2015
- The CRAPome: a contaminant repository for affinity purification–mass spectrometry dataNature Methods, 2013
- Modulation of aryl hydrocarbon receptor activity by four and a half LIM domain 2The International Journal of Biochemistry & Cell Biology, 2009
- MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantificationNature Biotechnology, 2008
- ARA24/Ran enhances the androgen-dependent NH2- and COOH-terminal interaction of the androgen receptorBiochemical and Biophysical Research Communications, 2008
- Serum response factor: toggling between disparate programs of gene expressionJournal of Molecular and Cellular Cardiology, 2003
- The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogensThe Journal of Steroid Biochemistry and Molecular Biology, 1992